HomeCompareAQSZF vs CL

AQSZF vs CL: Dividend Comparison 2026

AQSZF yields 51282.05% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AQSZF wins by $6.164318307325471e+23M in total portfolio value
10 years
AQSZF
AQSZF
● Live price
51282.05%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.164318307325471e+23M
Annual income
$614,076,267,853,163,140,000,000,000,000.00
Full AQSZF calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — AQSZF vs CL

📍 AQSZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAQSZFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AQSZF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AQSZF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AQSZF
Annual income on $10K today (after 15% tax)
$4,358,974.36/yr
After 10yr DRIP, annual income (after tax)
$521,964,827,675,188,650,000,000,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, AQSZF beats the other by $521,964,827,675,188,650,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AQSZF + CL for your $10,000?

AQSZF: 50%CL: 50%
100% CL50/50100% AQSZF
Portfolio after 10yr
$3.0821591536627355e+23M
Annual income
$307,038,133,926,581,570,000,000,000,000.00/yr
Blended yield
99.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

AQSZF
No analyst data
Altman Z
-297.9
Piotroski
3/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AQSZF buys
0
CL buys
0
No recent congressional trades found for AQSZF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAQSZFCL
Forward yield51282.05%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$6.164318307325471e+23M$41.0K
Annual income after 10y$614,076,267,853,163,140,000,000,000,000.00$5,451.69
Total dividends collected$6.16277212408334e+23M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: AQSZF vs CL ($10,000, DRIP)

YearAQSZF PortfolioAQSZF Income/yrCL PortfolioCL Income/yrGap
1← crossover$5,138,905$5,128,205.13$11,014$313.84+$5.13MAQSZF
2$2,468,429,435$2,462,930,806.71$12,200$415.44+$2468.42MAQSZF
3$1,108,293,458,836$1,105,652,239,339.88$13,607$553.09+$1108293.45MAQSZF
4$465,133,359,857,093$463,947,485,856,138.75$15,301$741.41+$465133359.84MAQSZF
5$182,471,032,796,869,920$181,973,340,101,822,850.00$17,374$1,002.00+$182471032796.85MAQSZF
6$66,912,846,333,441,070,000$66,717,602,328,348,430,000.00$19,958$1,367.44+$66912846333441.05MAQSZF
7$22,936,650,503,380,730,000,000$22,865,053,757,803,946,000,000.00$23,243$1,887.87+$22936650503380732.00MAQSZF
8$7,349,564,359,975,759,000,000,000$7,325,022,143,937,141,000,000,000.00$27,512$2,642.43+$7349564359975758848.00MAQSZF
9$2,201,460,634,938,307,300,000,000,000$2,193,596,601,073,133,400,000,000,000.00$33,197$3,759.22+$2.2014606349383072e+21MAQSZF
10$616,431,830,732,547,100,000,000,000,000$614,076,267,853,163,140,000,000,000,000.00$40,973$5,451.69+$6.164318307325471e+23MAQSZF

AQSZF vs CL: Complete Analysis 2026

AQSZFStock

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Full AQSZF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this AQSZF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AQSZF vs SCHDAQSZF vs JEPIAQSZF vs OAQSZF vs KOAQSZF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.